Medical Treatments for Prostate CancerThere are many different medical treatments for prostate cancer that involve the clinical care of a healthcare professional. These treatments include expectant therapy, surgery, radiation therapy, hormone therapy, and chemotherapy. Expectant therapy is to carefully observe and monitor the prostate cancer. Because prostate cancer cells often spread very slowly, many older men who have the disease may not need more extensive treatment. However, expectant therapy usually includes routine physician examinations, including digital rectal exams and PSA tests. The different types of surgery for prostate cancer are radical prostatectomy - an open-surgery procedure in which the entire prostate gland and surrounding tissue are removed. Transurethral resection of the prostate (TURP) - surgery to remove part of the prostate gland that surrounds the urethra. Cryosurgery - this procedure involves killing the cancer cells by freezing them with a small metal tool placed in the tumor. Side effects of prostate cancer surgery include incontinence and impotence. Incontinence is the inability to control urine and may result in dribbling of urine, especially immediately after surgery. Normal control usually returns within weeks or months after surgery. Impotence is the inability to achieve an erection. For a month, or so, after surgery, most men are not able to get an erection. Eventually, approximately 40 to 60 percent of men will be able to get an erection sufficient for sexual intercourse, but without ejaculation of semen, since removal of the prostate gland prevents that process.Radiation therapy uses high energy rays to kill or shrink cancer cells, and to decrease their ability to divide. Radiation is often used to treat prostate cancer that is still confined to the prostate gland, or has spread only to nearby tissue. If the disease is advanced, radiation may be used to reduce the size of the tumor and to provide relief from symptoms. Possible side effects of radiation for prostate cancer may include diarrhea, with or without blood in the stool, and colitis, problems associated with urination, a degree of impotence (inability to get an erection), which may occur within two years of radiation therapy. The goal of hormone therapy is to lower the level of male hormones in the body, particularly testosterone. Hormone therapy does not cure the cancer, and is often used to treat persons whose cancer has spread or recurred after treatment. Produced mainly in the testicles, testosterone causes prostate cancer cells to grow. Thus, reduced testosterone levels can make the prostate cancer shrink and become less active. Most studies show that hormone therapy works better if it is started early. Chemotherapy is the use of powerful, anti-cancer medications to kill cancer cells.. Hospitalization may be needed to monitor treatment and chemotherapy's side effects. Common side effects of chemotherapy include: nausea and vomiting, hair loss, anemia, reduced ability of blood to clot, mouth sores, increased likelihood of developing infections, fatigue. Most side effects disappear once treatment is stopped. |
| dosimetry prostate |
|
Permanent Prostate Brachytherapy: The Significance of Postimplant In prostate brachytherapy (PB), some form of postimplant dosimetric assessment . The dosimetry of prostate brachytherapy-induced urethral strictures. Real-Time Dosimetry and Optimization of Prostate Photodynamic For the second year of this 3-year grant. We have completed specific aim 2 of the project, ie, light dose calculation and optimization, and characterization Prostate brachytherapy post implant dosimetry: A comparison Segmental urethral dosimetry and urinary morbidity following prostate brachytherapy. No presentation available Meeting: 2007 Prostate Cancer Symposium Protein Adducts of the Prostate Carcinogen PhlP in Children Descriptors : *PROTEINS, *ANTIBODIES, *MASS SPECTROMETRY, *PROSTATE CANCER, CARCINOGENS, EPIDEMIOLOGY, HIGH SENSITIVITY, DOSIMETRY, PROSTATE GLAND, PROSTATE CANCER - CT-Guided Post-Brachytherapy Dosimetry Study A new imaging modality that may more accurately assess our post-procedural implant dosimetry in some patients is MRI-based prostate implant dosimetry. BIPM metrology portal challenges ⢠⢠⢠⢠⢠CCRI/CIPM electron dosimetry synchrotron radiation digital activity comparisons by internet brachytherapy dosimetry prostate cancer MCNP modeling of prostate brachytherapy and organ dosimetry Title:, MCNP modeling of prostate brachytherapy and organ dosimetry. Author:, Usgaonker, Susrut Rajanikant. Abstract:, Using the computer code Monte Carlo Rectal Morbidity Following I-125 Prostate Brachytherapy in Rectal Morbidity Following I-125 Prostate Brachytherapy in Relation to Dosimetry. Toshio Ohashi1,, Atsunori Yorozu1, Kazuhito Toya1, Shiro Saito2, Dosimetry accuracy as a function of seed localization uncertainty The variation of permanent prostate brachytherapy dosimetry as a function of seed localization uncertainty was investigated for I-125 implants with seed Nature Clinical Practice Urology | About the authors : Dose His areas of interest include real-time dosimetry prostate seed brachytherapy, extra-cranial stereotactic radiation therapy for prostate and lung cancer, Dosimetric characterization of a new /sup 125/lodine brachytherapy, 1-125 dosimetry, prostate. I. INTRODUCTION. Isotopes that emit principally low-energy gamma rays and. that can be manufactured to provide PET-Based Radiation Dosimetry in Man of F Key Words: FDHT; dosimetry; prostate cancer;. 18. F; androgens. J Nucl Med 2004; 45:1966â“1971. P. rostate cancer is one of the most important cancers in ScienceDirect - Medical Dosimetry : Prostate implant nomograms for J.J. Prete, B.R. Prestidge, W.S. Bice et al., A survey of physics and dosimetry practice of permanent prostate brachytherapy in the United States. ScienceDirect - Academic Radiology : Computing Intraoperative Computing Intraoperative Dosimetry for Prostate Brachytherapy Using TRUS and There is a need to provide real-time dosimetric feedback during prostate IngentaConnect Improved Biochemical Control and Clinical Disease Dosimetric prostate coverage was superior for group 2. The mean percentage of the prescription dose delivered to 90% of the prostate volume (%D90) was 75% IngentaConnect Optimizing target coverage by dosimetric feedback Purpose: Postimplant dosimetry of permanent prostate implants shows a loss of coverage compared to the preplan. One contributing factor is needle Comparison of urethral diameters for calculating the urethral dose a learning tool for CT-based postimplant dosimetry prostate. brachytherapy. Radiother Oncol 2006;81:303â“8. 19. Tanaka O, Hayashi S, Matsuo M, Sakurai K, Energy Citations Database (ECD) - - Document #20432625 Methods and Materials: Between 7/95 and 8/99, 297 patients underwent{sup 125}I implants for T1-T2 prostate cancer and had CT-based dosimetry performed (TG43 |
| dosimetry prostate |
|
dallas raines prostate cancer bob hunter prostate cancer cancer in lymph node prostate add information prostate site |